Tag: infants
-
RSV Wave Hits the US: Protecting Babies This Season
RSV Returns with a New Surge in the United States A wave of respiratory syncytial virus (RSV) is sweeping across the United States, placing a growing burden on pediatric healthcare systems and raising concerns for parents of newborns and toddlers. Health officials say the current season could bring higher hospitalization rates for infants, who are…
-
RSV Immunization for Infants: What Parents Should Know
Understanding RSV and the role of immunization Respiratory syncytial virus (RSV) is a common cause of cold-like symptoms in many babies, but it can turn severe, especially for preterm infants, those with certain health conditions, or those born during RSV season. Vaccines and other preventive options aim to reduce the risk of severe RSV illness…
-
RSV vaccines for infants: what parents need to know
Understanding RSV and why vaccination matters for infants Respiratory syncytial virus (RSV) is a common infection that can cause serious illness in young children, especially infants and those with underlying health conditions. Most kids recover within a week or two, but RSV can lead to hospitalization for some babies due to bronchiolitis or pneumonia. Vaccination…
-
RSV Immunization for Infants: What Parents Need to Know
Understanding RSV and Why Immunization Matters Respiratory syncytial virus (RSV) is a common illness that can cause serious breathing problems in some babies. While most infants recover at home, RSV can lead to prolonged symptoms and, in vulnerable children, require medical care. Immunization strategies are evolving, offering new ways to protect infants during the RSV…
-
Western Australia Faces Record RSV Season Despite Strong Immunisation Uptake
RSV in WA: A Record-Breaking Season Meets Strong Immunisation Western Australia is navigating what could be its worst respiratory syncytial virus (RSV) year on record. Latest health data show 11,551 RSV cases reported to the Department of Health as of Monday, just 104 cases shy of the peak set in 2022. While the numbers paint…
-
RSV in WA: Despite Strong Immunisation, Health Officials Fear Record Year
RSV in Western Australia: A record-chasing season despite high immunisation uptake Western Australia is approaching a potential record year for respiratory syncytial virus (RSV) cases, even as a broad immunisation program for infants and pregnant women helps blunt severe outcomes. Health authorities report 11,551 RSV notifications up to Monday, just 104 cases shy of the…
-
Prenatal Language Exposure: Can Babies Learn Before Birth?
Can a language learn before a baby is born? A growing body of evidence from neuropsychology suggests that the language brain may begin its remarkable wiring even before birth. In a study funded by NSERC (the Natural Sciences and Engineering Research Council of Canada) and conducted with researchers from the Université de Montréal, expectant mothers…
-
Non-Accidental Trauma NAT in Infants: Detection and Care
Introduction Non-accidental trauma (NAT), also referred to as non-accidental injury, remains a critical concern in pediatric practice. The term NAT encompasses injuries that are likely inflicted by a caregiver or another person, rather than caused by an accidental event. A structured approach to recognition, diagnosis, and family-centered care is essential to safeguard the child and…
-
Nirsevimab sharply reduces RSV hospitalizations in U.S. infants during 2024-2025 season
Real-world data show strong protection for U.S. infants As the United States navigates the 2024-2025 RSV season, several U.S. health networks published real-world analyses underscoring the protective effect of nirsevimab in infants. Across multiple settings, infants who received the preventive monoclonal antibody before RSV circulation experienced markedly lower rates of RSV-related hospitalizations compared with comparable…
-
Nirsevimab Slashes RSV Hospitalizations in US Infants During 2024-2025
Real‑world data show strong protection for US infants A recent research letter analyzing the 2024‑2025 RSV season indicates that administering nirsevimab to infants is associated with fewer hospitalizations due to RSV. While randomized trials proved safety and efficacy, real‑world data confirm that protection extends into everyday clinical practice, easing bed occupancy and the caregiving burden…